Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
The medication must be used within that window or discarded
Inflammatory marker changes (CRP, ESR) typically require 4 to 8 weeks to become measurable
Sources : American Medical Association
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
